These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26791067)

  • 1. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study.
    Wilkins JT; Li RC; Sniderman A; Chan C; Lloyd-Jones DM
    J Am Coll Cardiol; 2016 Jan; 67(2):193-201. PubMed ID: 26791067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Cao J; Nomura SO; Steffen BT; Guan W; Remaley AT; Karger AB; Ouyang P; Michos ED; Tsai MY
    J Clin Lipidol; 2020; 14(1):109-121.e5. PubMed ID: 31882375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study.
    Erbel R; Lehmann N; Churzidse S; Möhlenkamp S; Moebus S; Mahabadi AA; Schmermund A; Stang A; Dragano N; Grönemeyer D; Seibel R; Kälsch H; Bauer M; Bröcker-Preuss M; Mann K; Jöckel KH;
    Atherosclerosis; 2013 Aug; 229(2):531-40. PubMed ID: 23701995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness.
    Qu G; Zhang Z; Zhu H
    Lipids Health Dis; 2021 Jul; 20(1):80. PubMed ID: 34325713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein cholesterol/apolipoprotein B ratio is superior to apolipoprotein B alone in the diagnosis of coronary artery calcification.
    Chang TY; Chen JD
    Coron Artery Dis; 2021 Sep; 32(6):561-566. PubMed ID: 33394694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels.
    Sayed A; Peterson ED; Virani SS; Sniderman AD; Navar AM
    JAMA Cardiol; 2024 Aug; 9(8):741-747. PubMed ID: 38865115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
    Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
    Eur Heart J; 2024 Jul; 45(27):2410-2418. PubMed ID: 38700053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in Lipid Profiles During Young Adulthood and the Risk of Coronary Artery Calcium Incidence in Midlife: Insights From the CARDIA Study.
    Gao JW; Hao QY; Lin Y; Li ZH; Huang ZG; Bai ZQ; Zhang HF; Wu YB; Xiong ZC; You S; Wang JF; Zhang SL; Liu PM
    Circ Cardiovasc Imaging; 2024 Sep; 17(9):e016842. PubMed ID: 39268602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Low-density Lipoprotein Cholesterol on Coronary Artery Calcification Progression According to High-density Lipoprotein Cholesterol Levels.
    Lee DY; Kim JH; Park SE; Park CY; Oh KW; Park SW; Rhee EJ; Lee WY
    Arch Med Res; 2017 Apr; 48(3):284-291. PubMed ID: 28923331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
    Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
    Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Risk of Coronary Artery Calcification according to Different Lipid Parameters and Average Lipid Parameters.
    Yoo TK; Lee MY; Sung KC
    J Atheroscler Thromb; 2024 Aug; 31(8):1194-1214. PubMed ID: 38417908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.
    Sniderman AD; Islam S; Yusuf S; McQueen MJ
    Atherosclerosis; 2012 Dec; 225(2):444-9. PubMed ID: 23068583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
    Sniderman AD; St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
    Am J Cardiol; 2003 May; 91(10):1173-7. PubMed ID: 12745098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
    JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.